These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35174673)

  • 1. Disease Features and Gastrointestinal Microbial Composition in Patients with Systemic Sclerosis from Two Independent Cohorts.
    Andréasson K; Lee SM; Lagishetty V; Wu M; Howlett N; English J; Hesselstrand R; Clements PJ; Jacobs JP; Volkmann ER
    ACR Open Rheumatol; 2022 May; 4(5):417-425. PubMed ID: 35174673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts.
    Volkmann ER; Hoffmann-Vold AM; Chang YL; Jacobs JP; Tillisch K; Mayer EA; Clements PJ; Hov JR; Kummen M; Midtvedt Ø; Lagishetty V; Chang L; Labus JS; Molberg Ø; Braun J
    BMJ Open Gastroenterol; 2017; 4(1):e000134. PubMed ID: 28761687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome.
    Nguyen AD; Andréasson K; McMahan ZH; Bukiri H; Howlett N; Lagishetty V; Lee SM; Jacobs JP; Volkmann ER
    Semin Arthritis Rheum; 2023 Jun; 60():152185. PubMed ID: 36870237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic Sclerosis.
    Volkmann ER; Hoffmann-Vold AM; Chang YL; Lagishetty V; Clements PJ; Midtvedt Ø; Molberg Ø; Braun J; Jacobs JP
    Eur Med J (Chelmsf); 2020 Dec; 7():110-118. PubMed ID: 36711108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium.
    Volkmann ER; Chang YL; Barroso N; Furst DE; Clements PJ; Gorn AH; Roth BE; Conklin JL; Getzug T; Borneman J; McGovern DP; Tong M; Jacobs JP; Braun J
    Arthritis Rheumatol; 2016 Jun; 68(6):1483-92. PubMed ID: 26749064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement.
    Patrone V; Puglisi E; Cardinali M; Schnitzler TS; Svegliati S; Festa A; Gabrielli A; Morelli L
    Sci Rep; 2017 Nov; 7(1):14874. PubMed ID: 29093509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status.
    Natalello G; Bosello SL; Paroni Sterbini F; Posteraro B; De Lorenzis E; Canestrari GB; Gigante L; Verardi L; Ferraccioli G; Sanguinetti M; Gremese E
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):73-84. PubMed ID: 32865168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.
    McMahan ZH; Tucker AE; Perin J; Volkmann ER; Kulkarni S; Ziessman HA; Pasricha PJ; Wigley FM
    Arthritis Care Res (Hoboken); 2022 Mar; 74(3):442-450. PubMed ID: 33064934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal microbiome in scleroderma: recent progress.
    Volkmann ER
    Curr Opin Rheumatol; 2017 Nov; 29(6):553-560. PubMed ID: 28719392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.
    Suliman Y; Kafaja S; Oh SJ; Alemam M; Bagnato G; Abignano G; Singh RR; Barlow G; Liu X; Valera I; Morales W; Rezaie A; Pimentel M; Del Galdo F; Furst DE
    Clin Rheumatol; 2021 Jun; 40(6):2277-2284. PubMed ID: 33231773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth.
    Levin D; De Palma G; Zou H; Bazzaz AHZ; Verdu E; Baker B; Pinto-Sanchez MI; Khalidi N; Larché MJ; Beattie KA; Bercik P
    J Scleroderma Relat Disord; 2021 Oct; 6(3):290-298. PubMed ID: 35382497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease.
    Andréasson K; Alrawi Z; Persson A; Jönsson G; Marsal J
    Arthritis Res Ther; 2016 Nov; 18(1):278. PubMed ID: 27894337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the Gastrointestinal Microbiome in Systemic Sclerosis.
    Bellocchi C; Volkmann ER
    Curr Rheumatol Rep; 2018 Jun; 20(8):49. PubMed ID: 29943234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiome profiling in systemic sclerosis: a metagenomic approach.
    Tan TC; Chandrasekaran L; Leung YY; Purbojati R; Pettersson S; Low AHL
    Clin Exp Rheumatol; 2023 Aug; 41(8):1578-1588. PubMed ID: 36826808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis.
    Lemos MPC; Zucoloto TG; Oliveira MC; de Oliveira GLV
    J Clin Rheumatol; 2022 Mar; 28(2):e568-e573. PubMed ID: 34030162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.